Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Professor Anna Schuh awarded funding from the NIHR RIGHT programme

Department Funding Research

The NIHR has invested £34 million of funding into global health research projects to tackle epilepsy, infection-related cancers and severe stigmatising skin diseases in low- and middle-income countries (LMICs).

The NIHR Research and Innovation for Global Health Transformation (RIGHT) programme has awarded Official Development Assistance (ODA) funding to eight projects led by teams made up of researchers in the UK and those in LMICs.

Professor Anna Schuh from the Department of Oncology is leading one of the eight projects, and will be investigating two new techniques to diagnose Epstein-Barr virus, a common cause of blood cancers in sub-Saharan Africa. Her research in Tanzania and Uganda aims to speed up diagnosis and treatment of the infection, reducing the mortality rate from these cancers.

 

For more information on the full recipients of funding for this programme grant, please go to https://www.nihr.ac.uk/news/nihr-invests-34-million-into-global-health-research-on-epilepsy-infection-related-cancers-and-severe-stigmatising-skin-diseases/22764

Similar stories

The Howat Foundation to fund Chair in Clinical Oncology

Oxford Cancer announce the endowment of a Chair in Clinical Oncology, thanks to generous philanthropic support from The Howat Foundation

New Oxford and Nottingham developed tool uses existing health records to predict people’s risk of developing lung cancer within the next 10 years

A team of researchers from the University of Oxford and the University of Nottingham have developed a new tool, called ‘CanPredict’, aimed at identifying the people most at risk of developing lung cancer over the next 10 years, and put them forward for screening tests earlier, saving time, money and, most importantly, lives.

Scientists find genetic ‘marker’ linked to serious side-effects from skin cancer treatment

New research from the Fairfax Group has identified a genetic marker that could be used to predict a patient’s risk of developing serious side-effects when undergoing immunotherapy treatment for metastatic melanoma.

Oxford gets £122m funding for healthcare research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients. The funding was awarded to the city’s two National Institute for Health and Care Research (NIHR) Biomedical Research Centres (BRC).

The Department represented at the European Radiation Research Society annual conference

Researchers from the Department of Oncology attend the prestigious European Radiation Research Society (ERRS) in annual conference in Catania, Italy to present their research in Radiation Oncology.

Funding to research metformin’s ability to delay or prevent cancers driven by the mutated TP53 gene

A research project embedded within the Metformin in Li Fraumeni (MILI) trial will investigate metformin’s mechanism of action when taken as a preventative for mTP53-driven cancers.